re.Mind Capital Research
Investment Thesis
re.Mind Capital describes itself as "the leading early-stage investor dedicated to mental health, brain health, and human flourishing." It is a specialist fund founded around 2020 by Christian Angermayer and his family office Apeiron Investment Group, together with partners Jan Hardorp and Max de Vere. Angermayer is best known for psychedelics-based mental health investing, including co-founding atai Life Sciences and seeding Compass Pathways. The fund treats neurotechnology, mental health and next-generation treatment platforms as one connected investment universe, and invests in companies with "radical new ideas to improve mental health and wellbeing globally."
Sector Focus
Third-party profiles (EU-Startups, Caplight, Neurofounders) list the focus areas as:
- New pharma, including psychedelic-adjacent and novel neuropsychiatric drug platforms
- New modalities for treating brain disorders
- Brain-computer interfaces (BCI) and neurostimulation devices
- Digital health and digital biomarkers for mental health
The firm's own site does not publish a portfolio or team page; both sit behind scripted sections that could not be read, so the portfolio and team below come from press releases and data providers.
Stage Focus
Public profiles are inconsistent. The fund led early seeds (Blackrock Neurotech, Ksana Health) and has joined Series A and B rounds (Sensorium, Motif, Precision Neuroscience). A directory entry cites seed and pre-seed; EU-Startups lists Series A/B; Tracxn says primarily Series A. Treat it as Seed through Series B, with the most evidence at Seed and Series A.
Check Size
Directory profiles cite a $100K minimum, a $5M maximum and a sweet spot near $1.5M. EU-Startups lists a typical investment of EUR 1.5M to 3M. These figures come from self-reported directory entries and are moderate confidence.
Lead Tendency
Mixed. re.Mind led Blackrock Neurotech's seed and Ksana Health's $2M seed (with a board seat held by Jan Hardorp). In later rounds such as Precision Neuroscience Series B, Sensorium Series A and Motif Series A it appears as a participant or co-investor.
Recent Activity
- Oct 2026: Bridge Neurotech seed (co-investor, per Caplight / CB Insights)
- Nov 2024: ANNA (Allied Network for Neurodevelopmental Advancement) seed
- Jan 2024: Motif Neurotech Series A ($18.75M)
- Jan 2023 / Feb 2023: Precision Neuroscience Series B ($41M)
- Nov 2022: Sensorium Therapeutics Series A
- Data providers report roughly 13 to 19 investments and about $146M in assets under management (low confidence). The firm appears to be actively investing.
Portfolio Highlights
- Blackrock Neurotech: BCI pioneer; re.Mind led its seed in 2021
- Precision Neuroscience: minimally invasive BCI, Series B 2023
- Motif Neurotech: implantable neurostimulator for depression
- Sensorium Therapeutics: neuropsychiatric drug discovery
- Neumora Therapeutics: neuroscience drug developer, 2021 Series A
- Ksana Health: passive behavioral monitoring for mental healthcare
- iLoF: personalised drug discovery
- ANNA and Bridge Neurotech: newer neurodevelopmental and neurotech seeds
- Strategic investor, with Apeiron, in neurocare group's financing round
The site's Stories page also features Delix Therapeutics, Alto Neuroscience, Small Pharma, OpenBCI, Alena and CereGate; the page does not say whether these are holdings, so they are not entered as portfolio companies.
Team
- Christian Angermayer: Founder; Apeiron Investment Group, atai Life Sciences co-founder
- Max de Vere: Co-founder and partner
- Jan Hardorp: Founding partner; takes board seats (for example Ksana Health)
- Joao Barbosa da Silva: Investor
- Katherine Jones: Investor
Decision Process
Partnership-led, with a small team of two to ten people. A partner typically takes the board seat on led rounds.
Founder Preferences
Scientifically and technically credible founders with radical approaches to mental and neurological health. The fund favors founders working at the intersection of neuroscience hardware, therapeutics and measurement.
Geographic Focus
Mainly the United States, with secondary activity in Europe (UK, Germany, Portugal). Registered in Malta (Sliema) with an office in London.